Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00923884 · ClinicalTrials.gov registry record

Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
546
Enrollment target

NCT00923884: Completed study, sponsored by National Cancer Institute (NCI).

NCT00923884 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 546 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00923884 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
546 participants
Enrollment target

Study Summary

Background: * The Lung Cancer section of the National Cancer Institute s Medical Oncology Branch is running a study to better understand which genes might be important in patients who are undergoing therapy for lung cancer. Objectives: * To find out if differences (also called polymorphisms) in specific genes lead to differences in outcomes (such as treatment success and survival rates) for patients who have been diagnosed with lung cancer. * To establish a repository of genetic information for future studies of these differences and their relation to lung cancer. Eligibility: * Any individual who has been diagnosed with lung cancer and is being treated through the National Cancer Institute. Design: * After entrance in this study, patients will provide information to the researchers on age, gender, race/ethnicity, treatments received and response to treatments, and other specific information about their disease. This information will be kept confidential. * Approximately half a tablespoon of blood will be drawn. * Patients will be treated for lung cancer with normal treatment methods, as if they had not been enrolled in the study * Some patients may be offered the option of enrolling in separate research protocols for cancer treatment, involving chemotherapy, surgery, or radiation.

Trial Details

FieldValue
Enrollment Target 546 participants
Start Date 2009-03-18
Est. Completion 2018-04-20
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00923884 record still lists

NCT00923884 is an observational study that tracks outcomes without assigning an intervention. The registered 546 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00923884 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00923884 about?

NCT00923884 is a clinical study titled "Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer". Background: * The Lung Cancer section of the National Cancer Institute s Medical Oncology Branch is running a study to better understand which genes might be important in patients who are undergoing therapy for lung cancer. Objectives: * To find out if differences (also called polymorphisms) in s...

What is the current status of trial NCT00923884?

This trial is currently completed. The enrollment target is 546 participants. The study started on 2009-03-18. Estimated completion is 2018-04-20.

Who is sponsoring clinical trial NCT00923884?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03572374 · 546 participants · NA

    Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job

  • NCT05937685 · 546 participants · NA

    Reducing Blood Pressure in Patients With High Cardiovascular Risk

  • NCT06416150 · 546 participants · NA

    Reducing Urban Cervical Cancer Disparities

  • NCT06850922 · 546 participants · Phase 1

    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00923884, the US trial registry maintained by the National Library of Medicine. NCT00923884 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.